Brussels Pharma Lobby Urges EU Action

The Brussels-based pharmaceutical lobby is calling for increased EU action regarding legislation, specifically concerning the approval process for new drugs. They emphasize the need for faster movement through clinical trials and authorization pathways. This push reflects concerns about delays impacting patient access to innovative treatments and the competitiveness of the European pharmaceutical industry.

Summarized from the sources above. Read the originals for the full story.